Kong MW, Yu Y, Wan Y, Gao Y, Zhang CX. From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies. World J Gastrointest Oncol 2024; 16(11): 4518-4521 [PMID: 39554736 DOI: 10.4251/wjgo.v16.i11.4518]
Corresponding Author of This Article
Chun-Xiang Zhang, MD, Dean, Professor, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. zhangchx999@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4518-4521 Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4518
From biomarker discovery to combined therapies: Advancing hepatocellular carcinoma treatment strategies
Mo-Wei Kong, Yang Yu, Ying Wan, Yu Gao, Chun-Xiang Zhang
Mo-Wei Kong, Yang Yu, Department of Cardiology, Southwest Medical University, Luzhou 646000, Sichuan Province, China
Ying Wan, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, Sichuan Province, China
Yu Gao, Department of Endocrinology, The Affiliated Hospital of Chengde Medical College, Chengde 067000, Hebei Province, China
Chun-Xiang Zhang, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, Luzhou 646000, Sichuan Province, China
Co-first authors: Mo-Wei Kong and Yang Yu.
Author contributions: Kong MW and Yu Y wrote the manuscript; Designation of Kong MW and Yu Y as joint first authors are based on three main reasons; Kong MW and Yu Y contributed efforts of equal substance throughout the research process. Selecting these researchers as joint first authors acknowledge and respect this equal contribution, while recognizing the spirit of teamwork and collaboration of this study; Zhang CX provided crucial suggestions and guidance for the writing; Wan Y and Gao Y reviewed and revised the manuscript; all authors read and approved the final manuscript.
Supported byNational Natural Science Foundation of China, No. U23A20398 and No. 82030007; and Sichuan Science and Technology Program, No. 2022YFS0578.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Xiang Zhang, MD, Dean, Professor, Department of Pharmacology and Rush University Cardiovascular Research Center, Rush University Medical Center, No. 25 Taiping Street, Luzhou 646000, Sichuan Province, China. zhangchx999@163.com
Received: July 27, 2024 Revised: September 17, 2024 Accepted: October 9, 2024 Published online: November 15, 2024 Processing time: 90 Days and 5.4 Hours
Abstract
This editorial reviews advances in hepatocellular carcinoma (HCC) treatment, focusing on a triple therapy approach and biomarker discovery. Zhang et al discuss the synergistic potential of transarterial chemoembolization combined with tyrosine kinase inhibitors and PD-1 inhibitors. Meanwhile, Li et al identify protein tyrosine phosphatase non-receptor II (PTPN2) as a biomarker for poor prognosis and immune evasion in HCC. The studies highlight the importance of combined therapies and biomarkers in improving HCC treatment efficacy and patient outcomes, with PTPN2 emerging as a potential therapeutic target. This article supplements the aforementioned studies with more recent research advancements, focusing on the molecular mechanisms and clinical applications of biomarkers.
Core Tip: This article reviews the integration of novel combined therapies and biomarker identification in hepatocellular carcinoma (HCC) management. The studies by Zhang et al and Li et al explore the efficaciousness of a triple therapy involving transarterial chemoembolization, tyrosine kinase inhibitors, and PD-1 inhibitors, and the prognostic value of protein tyrosine phosphatase non-receptor II (PTPN2), respectively. These investigations underscore the significance of PTPN2 as a potential therapeutic target and highlight the promise of synergistic treatment strategies in enhancing HCC patient outcomes.
